PDCD1 and neoplasm: They emphasized that the tumor immune microenvironment, upon treatment with PD-1 inhibitor, affects the glucose metabolism in tumor cells and influences the uptake of 18F-FDG via factors such as the immune cell infiltration, activation and composition [22].